From: Targeting T cell malignancies using CAR-based immunotherapy: challenges and potential solutions
Challenge | Strategy | Reference |
---|---|---|
Fratricide | Targeting downregulated antigens (e.g., CD5) | [59] |
Genome editing of target antigen | ||
Targeting antigens with limited expression on T cells (e.g., CD30, CD37, TRBC1, CD1a) | ||
Tet-OFF expression system | [48] | |
Protein expression blockers (PEBLs) | [49] | |
Using NK cells or NK-92 cells | ||
T cell aplasia | Targeting antigens with limited expression on T cells (e.g., CD30, CD37, TRBC1, CD1a) | |
mRNA electroporation | Â | |
Adeno-associated viral (AAV) vector delivery | Â | |
Using NK cells or NK-92 cells | ||
Using γδ T cells |  | |
Suicide genes and safety switches | Â | |
Bridge to allogeneic hematopoietic stem cell transplant (HSCT) | Â | |
Product contamination | Allogeneic CAR T cells with TRAC locus editing | |
Using NK cells or NK-92 cells | ||
Using γδ T cells |  |